Australia markets close in 1 minute

Lisata Therapeutics, Inc. (8NE.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.48000.0000 (0.00%)
As of 01:30PM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 21.25M
Enterprise value -25.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.46
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.00

Trading information

Stock price history

Beta (5Y monthly) 1.08
52-week change 3-16.78%
S&P500 52-week change 326.43%
52-week high 34.0400
52-week low 31.7400
50-day moving average 32.6900
200-day moving average 32.3600

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 58.31M
Implied shares outstanding 69.08M
Float 86.75M
% held by insiders 118.78%
% held by institutions 18.83%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 315 Sept 2022

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.16%
Return on equity (ttm)-36.49%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -25.52M
Net income avi to common (ttm)-20.84M
Diluted EPS (ttm)-2.4000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)50.53M
Total cash per share (mrq)6.08
Total debt (mrq)305k
Total debt/equity (mrq)0.64%
Current ratio (mrq)8.18
Book value per share (mrq)5.91

Cash flow statement

Operating cash flow (ttm)-20.03M
Levered free cash flow (ttm)-14.36M